PSDV - pSivida Limited Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited

PSDV 1.220

+14.0%

Mar 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	8/30/2010 8:17:24 PM
	of 421

FDA grants priority review to Alimera drug Iluvien FDA grants priority review to potential Alimera treatment for diabetic macular edema ShareretweetEmailPrintCompanies:Alimera Sciences, Inc. On Monday August 30, 2010, 7:01 pm ATLANTA (AP) -- Alimera Sciences Inc. said Monday regulators granted priority review to its potential diabetic macular edema treatment, Iluvien. The Food and Drug Administration decision sets a six-month review timetable for the drug's application instead of the normal 10 months. That could result in a potential approval in December because the drug's application was submitted at the end of June. Diabetic macular edema can lead to distorted or loss of vision. Alimera, which specializes in prescription ophthalmic drugs, is conducting two late-stage trials on Iluvien that involve 956 patients to evaluate its safety and effectiveness. Shares of Alimera rose 40 cents, or nearly 5 percent, to $8.50 in after-hours trading Monday. finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next